209 related articles for article (PubMed ID: 2015395)
21. [A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].
Fujiwara M; Satou N; Izumi N; Shibasaki Y; Higashimura M; Tsukada N; Koike T
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1793-8. PubMed ID: 18030012
[TBL] [Abstract][Full Text] [Related]
22. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
Russo D; Malagola M; de Vivo A; Fiacchini M; Martinelli G; Piccaluga PP; Damiani D; Candoni A; Michielutti A; Castelli M; Testoni N; Ottaviani E; Rondoni M; Pricolo G; Mazza P; Zuffa E; Zaccaria A; Raspadori D; Bocchia M; Lauria F; Bonini A; Avanzini P; Gugliotta L; Visani G; Fanin R; Baccarani M
Br J Haematol; 2005 Oct; 131(2):172-9. PubMed ID: 16197446
[TBL] [Abstract][Full Text] [Related]
23. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
[TBL] [Abstract][Full Text] [Related]
24. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
Wiernik PH; Banks PL; Case DC; Arlin ZA; Periman PO; Todd MB; Ritch PS; Enck RE; Weitberg AB
Blood; 1992 Jan; 79(2):313-9. PubMed ID: 1730080
[TBL] [Abstract][Full Text] [Related]
25. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
[TBL] [Abstract][Full Text] [Related]
26. Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study.
Ohtake S; Miyawaki S; Kiyoi H; Miyazaki Y; Okumura H; Matsuda S; Nagai T; Kishimoto Y; Okada M; Takahashi M; Handa H; Takeuchi J; Kageyama S; Asou N; Yagasaki F; Maeda Y; Ohnishi K; Naoe T; Ohno R
Int J Hematol; 2010 Mar; 91(2):276-83. PubMed ID: 20054669
[TBL] [Abstract][Full Text] [Related]
27. Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial. Danish Society of Haematology Study Group on AML.
de Nully Brown P; Hoffmann T; Hansen OP; Boesen AM; Grønbaek K; Hippe E; Jensen MK; Thorling K; Storm HH; Pedersen-Bjergaard J
Leukemia; 1997 Jan; 11(1):37-41. PubMed ID: 9001416
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
[TBL] [Abstract][Full Text] [Related]
29. Toxicity and effectiveness of high-dose idarubicin during AML induction therapy: results of a pilot study in children.
Creutzig U; Körholz D; Niemeyer CM; Kabisch H; Graf N; Reiter A; Scheel-Walter H; Bender-Götze C; Behnisch W; Hermann J; Mann G; Ritter J; Zimmermann M
Klin Padiatr; 2000; 212(4):163-8. PubMed ID: 10994544
[TBL] [Abstract][Full Text] [Related]
30. Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia.
Lee JH; Kim H; Joo YD; Lee WS; Bae SH; Zang DY; Kwon J; Kim MK; Lee J; Lee GW; Lee JH; Choi Y; Kim DY; Hur EH; Lim SN; Lee SM; Ryoo HM; Kim HJ; Hyun MS; Lee KH;
J Clin Oncol; 2017 Aug; 35(24):2754-2763. PubMed ID: 28632487
[TBL] [Abstract][Full Text] [Related]
31. [Results of induction treatment with idarubicin for acute nonlymphoblastic leukemia in adults].
Hołowiecki J; Krzemień S; Rudzka E; Krawczyk M; Wojnar J; Hołowiecka B; Wacławik A; Wojciechowska M; Kachel L; Cedrych I
Acta Haematol Pol; 1994; 25(3):221-30. PubMed ID: 7992594
[TBL] [Abstract][Full Text] [Related]
32. 4-demethoxydaunorubicin (idarubicin) in combination with 1-beta-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia.
Berman E; Raymond V; Daghestani A; Arlin ZA; Gee TS; Kempin S; Hancock C; Williams L; Stevens YW; Clarkson BD
Cancer Res; 1989 Jan; 49(2):477-81. PubMed ID: 2910465
[TBL] [Abstract][Full Text] [Related]
33. A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
Jehn U; Zittoun R; Suciu S; Fiere D; Haanen C; Peetermans M; Löwenberg B; Willemze R; Solbu G; Stryckmans P
Haematol Blood Transfus; 1990; 33():277-84. PubMed ID: 1691132
[TBL] [Abstract][Full Text] [Related]
34. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.
Weick JK; Kopecky KJ; Appelbaum FR; Head DR; Kingsbury LL; Balcerzak SP; Bickers JN; Hynes HE; Welborn JL; Simon SR; Grever M
Blood; 1996 Oct; 88(8):2841-51. PubMed ID: 8874180
[TBL] [Abstract][Full Text] [Related]
35. High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission.
Stein AS; O'Donnell MR; Slovak ML; Nademanee A; Dagis A; Schmidt GM; Parker PM; Snyder DS; Smith EP; Somlo G; Margolin KA; Arber D; Niland J; Forman SJ
Leukemia; 2000 Jul; 14(7):1191-6. PubMed ID: 10914541
[TBL] [Abstract][Full Text] [Related]
36. Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside.
Hogan WJ; Letendre L; Litzow MR; Tefferi A; Hoagland HC; Pruthi RK; Kaufmann SH
Mayo Clin Proc; 2002 Aug; 77(8):760-2. PubMed ID: 12173711
[TBL] [Abstract][Full Text] [Related]
37. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.
Ohtake S; Miyawaki S; Fujita H; Kiyoi H; Shinagawa K; Usui N; Okumura H; Miyamura K; Nakaseko C; Miyazaki Y; Fujieda A; Nagai T; Yamane T; Taniwaki M; Takahashi M; Yagasaki F; Kimura Y; Asou N; Sakamaki H; Handa H; Honda S; Ohnishi K; Naoe T; Ohno R
Blood; 2011 Feb; 117(8):2358-65. PubMed ID: 20693429
[TBL] [Abstract][Full Text] [Related]
38. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
Jehn U; Heinemann V
Haematol Blood Transfus; 1990; 33():333-8. PubMed ID: 1691134
[TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
[TBL] [Abstract][Full Text] [Related]
40. Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposide.
Bolaños-Meade J; Karp JE; Guo C; Sarkodee-Adoo CB; Rapoport AP; Tidwell ML; Buddharaju LN; Chen TT
Leuk Res; 2003 Apr; 27(4):313-21. PubMed ID: 12531222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
